Delivering strong and sustainable performance

Fourth-quarter 2019 sales worldwide

- $8.3 billion
- +8.5% on organic basis

Sales performance across Abbott on organic basis

- 11.3% medical devices
- 5.8% nutrition
- 10.0% diagnostics
- 6.4% established pharmaceuticals

Full-year 2019 sales worldwide

- $32 billion
- +7.7% on organic basis

Full-year 2020 guidance

- $3.55 to $3.65
- Adjusted diluted EPS midpoint reflects double-digit growth
- 7% to 8% organic sales growth

Core laboratory diagnostics

- Sales US up 10% on organic basis

- Several businesses achieved double-digit growth in the fourth quarter

Established pharmaceuticals

- Sales US up 10% on organic basis

- Strong adoption of the Alinity family of advanced diagnostic testing technologies due to increased speed and efficiency in labs.
- Alinity®-S – Our most advanced system for screening blood and plasma was selected for use by the Australian Red Cross.

Medical devices

- Sales US up 11% on organic basis

- Fourth-quarter Abbott sales increased 7.1%.
- On a GAAP basis, Medical Devices sales increased 10%.
- MitraClip and FreeStyle Libre sales increased 27% and 59%, respectively.
- On a GAAP basis, Core Laboratory Diagnostics sales increased 8.4%.

Diagnostics

- Sales US up 6.4% on organic basis

- On a GAAP basis, full-year Abbott sales increased 4.3%.
- Adjusted diluted EPS excludes specified items. On a GAAP basis, full-year diluted EPS guidance is $2.35 to $2.45.
- 4. On a GAAP basis, full-year 2019 sales worldwide increased 7.7% on organic basis.

Nutrition

- Sales US up 5.8% on organic basis

- On a GAAP basis, full-year Nutrition sales increased 5.2%.

Established pharmaceuticals

- Sales US up 10% on organic basis

- On a GAAP basis, Established Pharmaceuticals sales increased 7.8%.
- our branded generics strategy in emerging markets continues to be highly successful.
- Sales performance was led by growth across several countries in Latin America and Asia.

Due to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements.

Some statements in this communication may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements.

Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors,” to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended December 31, 2018, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.